Guidelines: Difference between revisions
Jump to navigation
Jump to search
Urology4all (talk | contribs) |
Urology4all (talk | contribs) |
||
| Line 32: | Line 32: | ||
* [[Testosterone Deficiency (2018)]] | * [[Testosterone Deficiency (2018)]] | ||
* [[Erectile Dysfunction (2018)]] | * [[AUA & CUA: Erectile Dysfunction (2021 CUA, 2018 AUA)|Erectile Dysfunction (2018)]] | ||
* [[Peyronie's Disease (2015)]] | * [[Peyronie's Disease (2015)]] | ||
| Line 79: | Line 79: | ||
==== Prostate ==== | ==== Prostate ==== | ||
* Castrate-resistant Prostate Cancer (2021) | * [[CUA: Castrate-resistant Prostate Cancer (2021)|Castrate-resistant Prostate Cancer (2021)]] | ||
* Androgen Deprivation Therapy: Adverse Events & Management (2021) | * [[CUA: Androgen Deprivation Therapy: Adverse Events & Management (2021)|Androgen Deprivation Therapy: Adverse Events & Management (2021)]] | ||
* [[CUA: Metastatic Castration-naive and Castration-sensitive Prostate Cancer (2020)|Metastatic Castration-naive and Castration-sensitive Prostate Cancer (2020)]] | * [[CUA: Metastatic Castration-naive and Castration-sensitive Prostate Cancer (2020)|Metastatic Castration-naive and Castration-sensitive Prostate Cancer (2020)]] | ||
* Testosterone Suppression (2018) | * [[CUA: Testosterone Suppression (2018)|Testosterone Suppression (2018)]] | ||
* [[CUA: Prostate Cancer Screening (2017)|Prostate Cancer Screening (2017)]] | * [[CUA: Prostate Cancer Screening (2017)|Prostate Cancer Screening (2017)]] | ||
* Cancer Care Ontario: MRI in Prostate Cancer Diagnosis (2017) | * [[Cancer Care Ontario: MRI in Prostate Cancer Diagnosis (2017)]] | ||
* Prostate Cancer Active Surveillance (2015) | * [[CUA: Prostate Cancer Active Surveillance (2015)|Prostate Cancer Active Surveillance (2015)]] | ||
==== Bladder ==== | ==== Bladder ==== | ||
* [[CUA & AUA: Non-muscle Invasive Bladder Cancer (2021 CUA & 2020 AUA)|Non-muscle Invasive Bladder Cancer (2021)]] | * [[CUA & AUA: Non-muscle Invasive Bladder Cancer (2021 CUA & 2020 AUA)|Non-muscle Invasive Bladder Cancer (2021)]] | ||
* Advanced and Metastatic Urothelial Cancer (2019) | * [[CUA: Advanced and Metastatic Urothelial Cancer (2019)|Advanced and Metastatic Urothelial Cancer (2019)]] | ||
* Muscle-invasive Bladder Cancer (2019) | * [[CUA: Muscle-invasive Bladder Cancer (2019)|Muscle-invasive Bladder Cancer (2019)]] | ||
* Asymptomatic | * [[CUA: Asymptomatic Microscopic Hematuria (2008)|Asymptomatic Microscopic Hematuria (2008)]] | ||
==== Kidney ==== | ==== Kidney ==== | ||
* Follow-up Localized RCC (2018) | * [[CUA: Follow-up Localized RCC (2018)|Follow-up Localized RCC (2018)]] | ||
* Cystic Renal Lesions (2017) | * [[CUA: Cystic Renal Lesions (2017)|Cystic Renal Lesions (2017)]] | ||
* Small Renal Masses (2015) | * [[CUA: Small Renal Masses (2015)|Small Renal Masses (2015)]] | ||
* Surgical Management of RCC (2014) | * [[CUA: Surgical Management of RCC (2014)|Surgical Management of RCC (2014)]] | ||
* [[CUA: RCC Genetic Screening (2013)|RCC Genetic Screening (2013)]] | * [[CUA: RCC Genetic Screening (2013)|RCC Genetic Screening (2013)]] | ||
| Line 106: | Line 106: | ||
==== Andrology ==== | ==== Andrology ==== | ||
* Peyronie's Disease (2018) | * [[CUA: Peyronie's Disease (2018)|Peyronie's Disease (2018)]] | ||
* Erectile Dysfunction (2021) | * Erectile Dysfunction (2021) | ||
Revision as of 13:48, 11 November 2022
AUA Guidelines
Oncology
Prostate
- Clinically Localized Prostate Cancer (2022)
- Advanced Prostate Cancer (2020)
- Adjuvant and Salvage Radiotherapy After Prostatectomy (2019)
- Prostate Cancer Screening (2018)
- Clinically Localized Prostate Cancer (2017)
Bladder
- Muscle-invasive Bladder Cancer (2020)
- Non-muscle Invasive Bladder Cancer (2020)
- Microscopic Hematuria (2020)
- Muscle-invasive Bladder Cancer (2017)
- Non-muscle Invasive Bladder Cancer (2016)
Kidney
Testicular
- (2019) Included in Testicular Tumours Chapter Notes
Non-oncology
Andrology
Functional
- Surgical Management BPH (2018)
- AUA/CUA Mesh Position Statement (2019)
- Incontinence after Prostate Therapy (2019)
- Female SUI (2017)
Infections and Inflammation
Pediatrics
Stones
Other
Contribute
- Interstitial cystitis/bladder pain syndrome (2022)
- BPH (2021)
- Infertility (2021)
- Priapism (2021)
- Neurogenic LUTD (2021)
- Disorders of ejaculation (2020)
- OAB (2019)
- Antibiotic Prophylaxis (2019)
- Cryptorchidism (2018)
- Peyronie's disease (2015)
CUA Guidelines
Oncology
Prostate
- Castrate-resistant Prostate Cancer (2021)
- Androgen Deprivation Therapy: Adverse Events & Management (2021)
- Metastatic Castration-naive and Castration-sensitive Prostate Cancer (2020)
- Testosterone Suppression (2018)
- Prostate Cancer Screening (2017)
- Cancer Care Ontario: MRI in Prostate Cancer Diagnosis (2017)
- Prostate Cancer Active Surveillance (2015)
Bladder
- Non-muscle Invasive Bladder Cancer (2021)
- Advanced and Metastatic Urothelial Cancer (2019)
- Muscle-invasive Bladder Cancer (2019)
- Asymptomatic Microscopic Hematuria (2008)
Kidney
- Follow-up Localized RCC (2018)
- Cystic Renal Lesions (2017)
- Small Renal Masses (2015)
- Surgical Management of RCC (2014)
- RCC Genetic Screening (2013)
Non-oncology
Andrology
- Peyronie's Disease (2018)
- Erectile Dysfunction (2021)
Functional
- Neurogenic Lower Urinary Tract Dysfunction (2019)
- Male LUTS/BPH (2018)
- CUA/AUA Mesh Position Statement (2019)
- Overactive Bladder (2017)
Infections and Inflammation
- CUA/AUA Recurrent UTI (2019)
- Antibiotic Prophylaxis (2015)
- Chronic Scrotal Pain (2018)
- Interstitial Cystitis (2016)
Infertility
- Azoospermia (2015)
Pediatrics
- Circumcision (2018)
- Antenatal hydronephrosis (2017)
- Cryptorchidism (2017)
- Multicystic Dysplastic Kidney in the Neonate (2015)
Stones
- Evaluation and Medical Management of Stones (2016)
- Ureteral Calculi (2015)
Other
- Vasectomy (2016)
- Adrenal Mass (2011)
- Radiation-induced Hemorrhagic Cystitis (2018)
- VTE Prophylaxis (2019)
Contribute
- Ureteral calculi (2022)
- Pediatric bladder dysfunction (2021)
- Sporadic angiomyolipomas (2020)
- Male urethral stricture (2020)
- Catheter use (2020)
- Renal mass biopsy (2019)
- Pheochromocytoma surveillance (2019)
- Pediatric hemorrhagic cystitis (2019)